YKL-40 Downregulation Is a Key Factor to Overcome Temozolomide Resistance in a Glioblastoma Cell Line

Oncology Reports - Greece
doi 10.3892/or.2014.3195
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

Metformin and Temozolomide, a Synergic Option to Overcome Resistance in Glioblastoma Multiforme Models

Oncotarget
Oncology
2017English

Chronic Physiological Hypoxia and High Glucose Concentration Promote Resistance of T98G Glioblastoma Cell Line to Temozolomide

Drug Designing: Open Access
2014English

YKL-40 Expression Is Associated With Poorer Response to Radiation and Shorter Overall Survival in Glioblastoma

Clinical Cancer Research
Cancer ResearchOncology
2005English

A Novel Enhancer Regulates MGMT Expression and Promotes Temozolomide Resistance in Glioblastoma

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2018English

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma

Neurologia Medico-Chirurgica
SurgeryNeurology
2018English

Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma

Frontiers in Pharmacology
Pharmacology
2020English

Augmented HR Repair Mediates Acquired Temozolomide Resistance in Glioblastoma

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2016English

Genetic Alterations Associated With Acquired Temozolomide Resistance in SNB-19, a Human Glioma Cell Line

Molecular Cancer Therapeutics
Cancer ResearchOncology
2006English

Epidermal Growth Factor (EGF) Induces a Phenotypic Switch of a Human Glioblastoma Cell Line to Neurospheres

Microscopy and Microanalysis
Instrumentation
2002English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy